by mpzzqmvj | Dec 18, 2023 | Press Releases
Ongoing pivotal Phase 3 study (“TransportNPC™”) evaluating Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1 (NPC1) FDA feedback provides direction for the comparative interim analysis With aligned strategy, interim...
by mpzzqmvj | Nov 21, 2023 | Press Releases
Pivotal Phase 3 global study (TransportNPC™) evaluating Trappsol® Cyclo™ for Niemann-Pick Disease Type C1 (“NPC1”) to be highlighted in a platform presentation GAINESVILLE, Fla. – Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo...
by mpzzqmvj | Nov 15, 2023 | Press Releases
Strong pace of enrollment continues in pivotal Phase 3 global study (TransportNPC™) evaluating Trappsol® Cyclo™ for Niemann-Pick Disease Type C1 (“NPC1”) Merger with Applied Molecular Transport, Inc. (“AMT”) on track to close...
by mpzzqmvj | Oct 23, 2023 | Press Releases
Issues New Warrants to this Investment Group for Possible Additional Funding of Up to $3.47 Million (if exercised) GAINESVILLE, Fla. – Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage...
by mpzzqmvj | Oct 5, 2023 | Press Releases
Live webcast presentation on Thursday, October 12th at 12:00 PM ET GAINESVILLE, Fla. – Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing...
by mpzzqmvj | Sep 21, 2023 | Press Releases
Combined company will operate as Cyclo Therapeutics with primary focus on advancing Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1 (NPC1) At closing combined Company will have approximately $13.7 million cash on hand to fund operations...
